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Abstract
Following an application from Specialised Nutrition Europe (formerly IDACE), submitted for
authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the
Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was
asked to deliver an opinion on the scientiﬁc substantiation of a health claim related to calcium and
contribution to the normal development of bones. The Panel considers that calcium is sufﬁciently
characterised and that contribution to the normal development of bones is a beneﬁcial physiological
effect. The target population proposed by the applicant is infants (from birth) and young children up
to 3 years of age. The Panel has previously assessed a claim on calcium and normal growth and
development of bone with a favourable outcome. The target population was children and adolescents.
The Panel considers that the role of calcium in the development of bones applies to all ages including
infants and young children up to 3 years of age. The Panel concludes that a cause and effect
relationship has been established between the dietary intake of calcium and contribution to the normal
development of bones.
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Summary
Following an application from Specialised Nutrition Europe (formerly IDACE), submitted for
authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the
Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was
asked to deliver an opinion on the scientiﬁc substantiation of a health claim related to calcium and
contribution to the normal development of bones.
The scope of the application was proposed to fall under a health claim referring to children’s
development and health.
The general approach of the NDA Panel for the evaluation of health claim applications is outlined in
the EFSA general guidance for stakeholders on health claim applications.
The food constituent that is the subject of the health claim is calcium, which is an essential nutrient
and can be measured in foods by established methods. The Panel considers that calcium is sufﬁciently
characterised.
The claimed effect proposed by the applicant is that calcium ‘is important for the development of
bones’. The target population proposed by the applicant is infants (from birth) and young children up
to 3 years of age. The Panel considers that contribution to the normal development of bones is a
beneﬁcial physiological effect.
The Panel has previously assessed a claim on calcium and normal growth and development of bone
with a favourable outcome. The target population was children and adolescents. The Panel considers
that the role of calcium in the development of bones applies to all ages including infants and young
children up to 3 years of age.
The Panel concludes that a cause and effect relationship has been established between the dietary
intake of calcium and contribution to the normal development of bones.
The following wording reﬂects the scientiﬁc evidence: ‘Calcium contributes to the normal
development of bones’.
Calcium and development of bones
www.efsa.europa.eu/efsajournal 3 EFSA Journal 2016;14(10):4587
Table of contents
Abstract.................................................................................................................................................... 1
Summary.................................................................................................................................................. 3
1. Introduction................................................................................................................................... 5
1.1. Background and Terms of Reference as provided by the requestor..................................................... 5
1.2. Interpretation of the Terms of Reference.......................................................................................... 5
1.3. Additional information..................................................................................................................... 5
2. Data and methodologies ................................................................................................................. 5
2.1. Data.............................................................................................................................................. 5
2.1.1. Information provided by the applicant ............................................................................................. 5
2.1.2. Data provided by the applicant........................................................................................................ 6
2.2. Methodologies................................................................................................................................ 6
3. Assessment.................................................................................................................................... 6
3.1. Characterisation of the food/constituent........................................................................................... 6
3.2. Relevance of the claimed effect to human health.............................................................................. 7
3.3. Scientiﬁc substantiation of the claimed effect ................................................................................... 7
3.4. Panel’s comments on the proposed wording ..................................................................................... 7
3.5. Conditions and restrictions of use .................................................................................................... 7
4. Conclusions.................................................................................................................................... 7
Steps taken by EFSA ................................................................................................................................. 8
References................................................................................................................................................ 8
Abbreviations ............................................................................................................................................ 9
Calcium and development of bones
www.efsa.europa.eu/efsajournal 4 EFSA Journal 2016;14(10):4587
1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Regulation (EC) No 1924/20061 harmonises the provisions that relate to nutrition and health claims,
and establishes rules governing the Community authorisation of health claims made on foods. As a
rule, health claims are prohibited unless they comply with the general and speciﬁc requirements of this
Regulation, are authorised in accordance with this Regulation, and are included in the lists of
authorised claims provided for in Articles 13 and 14 thereof. In particular, Articles 14–17 of this
Regulation lay down provisions for the authorisation and subsequent inclusion of reduction in disease
risk claims and claims referring to children’s development and health in a Community list of permitted
claims.
According to Article 15 of this Regulation, an application for authorisation shall be submitted by the
applicant to the national competent authority of a Member State, which will make the application and
any supplementary information supplied by the applicant available to the European Food Safety
Authority (EFSA).
1.2. Interpretation of the Terms of Reference
EFSA is requested to evaluate the scientiﬁc data submitted by the applicant in accordance with
Article 16 of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an opinion
on the scientiﬁc substantiation of a health claim related to: calcium and contribution to the normal
development of bones.
The present opinion does not constitute, and cannot be construed as, an authorisation for the
marketing of calcium, a positive assessment of its safety, nor a decision on whether calcium is, or is
not, classiﬁed as a foodstuff. It should be noted that such an assessment is not foreseen in the
framework of Regulation (EC) No 1924/2006.
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions
of use as proposed by the applicant may be subject to changes, pending the outcome of the
authorisation procedure foreseen in Article 17 of Regulation (EC) No 1924/2006.
1.3. Additional information
A health claim on calcium and maintenance of normal bones has already been assessed by the
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) with a favourable outcome (EFSA NDA
Panel, 2009, 2010).
Moreover, a health claim on calcium and normal growth and development of bone has already been
assessed by the EFSA NDA Panel with a favourable outcome (EFSA NDA Panel, 2008a,b).
2. Data and methodologies
2.1. Data
2.1.1. Information provided by the applicant
Food/constituent as stated by the applicant:
• According to the applicant, the food which is the subject of the health claim is calcium.
Health relationship as claimed by the applicant:
• According to the applicant, calcium has ‘a critical role in the formation of bone’.
• The applicant stated that calcium ‘plays an important role during the growth of infants and
children’, and that calcium is ‘indispensable for proper and sufﬁcient formation of bones’.
Wording of the health claim as proposed by the applicant:
• The applicant has proposed the following wording: ‘Calcium is important for the development
of bones’.
1 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health
claims made on foods. OJ L 404, 30.12.2006, p. 9–25.
Calcium and development of bones
www.efsa.europa.eu/efsajournal 5 EFSA Journal 2016;14(10):4587
• The following alternative wordings, indicated by the applicant to be equivalent, were proposed:
‘Calcium contributes to/is involved in/is important for/plays an important role for/is necessary
for/participates to/is needed for/supports the (proper) development of/the (normal) function of
bones’.
Speciﬁc conditions of use as proposed by the applicant:
• The target population proposed by the applicant is infants (from birth) and young children up
to 3 years of age.
• According to the applicant, the quantities needed to be able to make the claim are as follows:
 For follow-on formulae, the content in calcium should be within the range set in Directive
2006/141/EC.
 For foods for special medical purposes, the content in calcium should be within the range
set in Directive 1999/21/EC.
 For processed cereal-based foods and baby foods, the content in calcium should reach at
least 15% of the Nutrient Reference Values set in Directive 2006/125/EC, i.e. 15% of
400 mg/100 g or 100 mL or per serving, as reconstituted.
 For foods other than follow-on formulae, processed cereal-based foods and baby foods,
the content in calcium should reach at least 15% of the Nutrient Reference Value set in
Directive 2006/141/EC, i.e. 15% of 550 mg/100 mL product ready for use.
2.1.2. Data provided by the applicant
Health claim application on calcium and contribution to the normal development of bones pursuant
to Article 14 of Regulation 1924/2006, presented in a common and structured format as outlined in
the Scientiﬁc and technical guidance for the preparation and presentation of applications for
authorisation of health claims (EFSA NDA Panel, 2011).
As outlined in the General guidance for stakeholders on health claim applications, it is the
responsibility of the applicant to provide the totality of the available evidence (EFSA NDA Panel, 2016).
2.2. Methodologies
The general approach of the NDA Panel for the evaluation of health claim applications is outlined in
the EFSA general guidance for stakeholders on health claim applications (EFSA NDA Panel, 2016).
3. Assessment
3.1. Characterisation of the food/constituent
The food constituent that is the subject of the health claim is calcium, which is an essential nutrient
and can be measured in foods by established methods.
Calcium occurs naturally in foods in various forms, which are generally well utilised by the body.
Different forms of calcium are authorised for addition to foods and for use in food supplements (Annex II of
Regulation (EC) No 1925/20062, Annex II of Directive 2002/46/EC3, Annex III of Directive 2006/141/EC4,
Annex IV of Directive 2006/125/EC5, Directive 2001/15/EC6). This evaluation applies to calcium
naturally present in foods and those forms authorised for addition to foods (Annex II of Regulation (EC)
No 1925/2006, Annex II of Directive 2002/46/EC, Annex III of Directive 2006/141/EC, Annex IV of
Directive 2006/125/EC, Directive 2001/15/EC).
The Panel considers that the food constituent, calcium, which is the subject of the health claim, is
sufﬁciently characterised.
2 Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of vitamins
and minerals and of certain other substances to foods. OJ L 404, 30.12.2006, p. 26–38.
3 Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the
Member States relating to food supplements. OJ L 183, 12.7.2002, p. 51–57.
4 Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending Directive
1999/21/EC Text with EEA relevance. OJ L 401, 30.12.2006, p. 1–33.
5 Commission Directive 2006/125/EC of 5 December 2006 on processed cereal-based foods and baby foods for infants and
young children. OJ L 339, 6.12.2006, p. 16–35.
6 Commission Directive 2001/15/EC of 15 February 2001 on substances that may be added for speciﬁc nutritional purposes in
foods for particular nutritional uses. OJ L 52, 22.2.2001, p. 19–25.
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3.2. Relevance of the claimed effect to human health
The claimed effect proposed by the applicant is that calcium ‘is important for the development of
bones’. The target population proposed by the applicant is infants (from birth) and young children up
to 3 years of age.
The Panel considers that contribution to the normal development of bones is a beneﬁcial
physiological effect.
3.3. Scientiﬁc substantiation of the claimed effect
The Panel has previously assessed a claim on calcium and maintenance of normal bones pursuant
to Article 13(1) of Regulation 1924/2006, i.e. for the general population (EFSA NDA Panel, 2009,
2010). The Panel considered that calcium is an important structural component of bones and
concluded that a cause and effect relationship has been established between the dietary intake of
calcium and the maintenance of normal bones (EFSA NDA Panel, 2009, 2010).
The Panel has also assessed a claim on calcium and normal growth and development of bone
pursuant to Article 14 of Regulation 1924/2006, i.e. referring to children’s development and health
(EFSA NDA Panel, 2008a,b). The Panel concluded that a cause and effect relationship has been
established between the intake of calcium and normal growth and development of bone (EFSA NDA
Panel, 2008a,b). The target population was children and adolescents (up to 18 years).
The Panel considers that the role of calcium in the development of bones applies to all ages,
including infants from birth and young children up to 3 years of age.
The Panel concludes that a cause and effect relationship has been established between the dietary
intake of calcium and contribution to the normal development of bones.
3.4. Panel’s comments on the proposed wording
The Panel considers that the following wording reﬂects the scientiﬁc evidence: ‘Calcium contributes
to the normal development of bones’.
3.5. Conditions and restrictions of use
The Panel considers that in order to bear the claim:
• Follow-on formulae should comply with the criteria for the composition of follow-on formulae
as laid down in Directive 2006/141/EC.
• Nutritionally complete foods for special medical purposes intended for use by infants and
nutritionally complete foods for special medical purposes other than those intended for use by
infants should comply with the criteria for the composition of these foods as laid down in
Directive 1999/21/EC.
• Processed cereal-based foods for infants and young children should comply with the criteria for
the composition of these foods as laid down in Directive 2006/125/EC.
• Other foodstuffs intended for infants and young children should provide at least 15% of the
reference values for the nutritional labelling of foods intended for infants and young children as
laid down in Directive 2006/141/EC.
Such amounts can easily be consumed as part of a balanced diet. The target population is infants
and young children up to 3 years of age. Dietary reference values for calcium have been set for infants
and young children (EFSA NDA Panel, 2015). No Tolerable Upper Intake Levels for calcium have been
set for this age group (EFSA NDA Panel, 2012).
4. Conclusions
On the basis of the data presented, the Panel concludes that:
• The food constituent, calcium, which is the subject of the health claim, is sufﬁciently
characterised.
• The claimed effect proposed by the applicant is that calcium ‘is important for the development
of bones’. The target population proposed by the applicant is infants (from birth) and young
children up to 3 years of age. Contribution to the normal development of bones is a beneﬁcial
physiological effect.
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• A cause and effect relationship has been established between the dietary intake of calcium and
contribution to the normal development of bones.
• The following wording reﬂects the scientiﬁc evidence: ‘Calcium contributes to the normal
development of bones’.
• In order to bear the claim, follow-on formulae should comply with the criteria for the
composition of follow-on formulae as laid down in Directive 2006/141/EC; nutritionally
complete foods for special medical purposes intended for use by infants and nutritionally
complete foods for special medical purposes other than those intended for use by infants
should comply with the criteria for the composition of these foods as laid down in Directive
1999/21/EC; processed cereal-based foods for infants and young children should comply with
the criteria for the composition of these foods as laid down in Directive 2006/125/EC; and
other foodstuffs intended for infants and young children should provide at least 15% of the
reference values for the nutritional labelling of foods intended for infants and young children as
laid down in Directive 2006/141/EC. Such amounts can easily be consumed as part of a
balanced diet. The target population is infants and young children up to 3 years of age. No
Tolerable Upper Intake Levels have been set for calcium for this age group.
Steps taken by EFSA
1) Health claim application on calcium and ‘is important for the development of bones’ pursuant
to Article 14 of Regulation (EC) No 1924/2006 (Claim Serial No: 0048_FR). Submitted by
Specialised Nutrition Europe (SNE, formerly IDACE), 9-31 Avenue des Nerviens, 1040
Brussels, Belgium.
2) This application was received by EFSA on 14 February 2008.
3) The scope of the application was proposed to fall under a health claim referring to children’s
development and health.
4) On 26 March 2008, during the validation process of the application, EFSA sent a request to
the applicant to provide missing information.
5) On 13 April 2016, EFSA received the missing information as submitted by the applicant.
6) The scientiﬁc evaluation procedure started on 2 May 2016.
7) During its meeting on 21 September 2016, the NDA Panel, having evaluated the data,
adopted an opinion on the scientiﬁc substantiation of a health claim related to calcium and
contribution to the normal development of bones.
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